This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Congenital Nephrotic Syndrome, Focal Segmental Glomerulosclerosis초점분절사구체경화증 선천성 신증후군 (초점분절사구체경화증 선천성신증후군)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: N04.1 (congenital nephrotic syndrome with focal and segmental glomerular lesions/hyalinosis/sclerosis or focal glomerulonephritis) | Special Copayment Reduction: V263 (rare disease)
B. SynonymsCongenital nephrotic syndrome with focal and segmental glomerular lesions | congenital nephrotic syndrome with focal and segmental hyalinosis | congenital nephrotic syndrome with focal and segmental sclerosis | congenital nephrotic syndrome with focal glomerulonephritis
C. Adult onsetLikelihood of first onset in adulthood: low — congenital or infantile-onset FSGS is mostly diagnosed within a few months to 1 year of age. Some hereditary FSGS (especially AD-inherited ACTN4, TRPC6, INF2 variants) may remain asymptomatic until adolescence or adulthood, but cases registered as congenital (N04.1) under the ICD classification presuppose early onset.
1. History1957: Rich described the FSGS histologic pattern → classification of hereditary FSGS systematized after identification of NPHS1/NPHS2 → discovery of podocyte structural genes such as α-actinin-4, TRPC6, INF2, CD2AP
2. CausesVariants in podocyte-related genes: in addition to NPHS1, NPHS2, WT1, LAMB2, PLCE1, also ACTN4 (α-actinin-4), TRPC6, INF2, CD2AP, APOL1, etc.
3. GeneticsAR (NPHS1, NPHS2, PLCE1), AD (ACTN4, TRPC6, INF2); age of onset varies by genotype; the younger the age of onset, the more likely a genetic cause
4. General epidemiologyMost common histologic type of pediatric steroid-resistant nephrotic syndrome (about 30–40%); high proportion of gene variants in congenital/infantile FSGS
5. PathophysiologyFSGS is the final common pathway of podocyte injury; hereditary podocyte protein abnormality → podocyte loss → glomerular scarring (sclerosis) → decline in glomerular function
6. SymptomsMassive proteinuria, generalized edema, hypoalbuminemia; may be accompanied by hematuria, hypertension; renal function declines relatively rapidly
7. SignsFindings specific to glomerulosclerosis: focal · segmental sclerosis and foot process effacement on light microscopy; hypertension, hematuria, and proteinuria may present simultaneously
8. ScreeningHigh-risk families: gene panel + urine protein testing; monitoring of carriers of low-risk variants such as NPHS2 p.R229Q
9. DiagnosisRenal biopsy (confirmation of focal · segmental sclerosis), gene panel (NPHS1, NPHS2, ACTN4, TRPC6, INF2, etc.), assessment of response to steroid treatment
10. TreatmentMostly SRNS; cyclosporine · tacrolimus as first-line immunosuppression; rituximab; ACE inhibitors/ARBs; kidney transplantation (considering risk of post-transplant recurrence)
11. PrognosisRate of progression to ESRD differs by FSGS variant type; relatively slow progression reported with homozygous NPHS2 variants; post-transplant recurrence is low in hereditary forms
12. PreventionGenetic counseling, prenatal/preimplantation genetic testing; early use of ACE inhibitors/ARBs to preserve renal function
13. References10 key references (with PMID or DOI)

1. History

Focal segmental glomerulosclerosis (FSGS) is a histopathological diagnosis referring to a pattern in which some glomeruli (focal) show sclerosis in part of the glomerular tuft (segmental). In 1957, the American pathologist Arnold Rich first described this histologic finding in cases of childhood nephrotic syndrome, and since then FSGS has been recognized as the most common histologic type of steroid-resistant nephrotic syndrome in children and adults.

FSGS was initially understood as a single disease, but over time it became clear that FSGS is the final common histologic response pattern of podocyte injury from various causes. Until the 1990s, FSGS observed in congenital nephrotic syndrome was mostly treated as of unknown cause, but since the 2000s, advances in molecular genetics have identified variants in various podocyte structural genes as causes of hereditary FSGS, led by NPHS1 (nephrin) and NPHS2 (podocin), followed by ACTN4 (α-actinin-4, 2000), TRPC6 (2005), INF2 (2010), CD2AP, and others.

In 2000, Kaplan et al. reported that autosomal dominant variants of the ACTN4 gene encoding α-actinin-4 cause adult-onset FSGS, and in 2005 Reiser et al. showed that TRPC6 channel variants cause FSGS. In 2010, Brown et al. reported that autosomal dominant variants of the INF2 (inverted formin 2) gene cause pediatric and adult FSGS. As a result, FSGS was established as a genetically heterogeneous group of disorders including both autosomal recessive (NPHS1, NPHS2, PLCE1, etc.) and autosomal dominant (ACTN4, TRPC6, INF2, etc.) modes of inheritance.

A subclassification of FSGS by histologic findings (Columbia classification: NOS, perihilar, cellular, tip, collapsing variant) was also established after 2004, and partial associations of histologic findings with genetic causes and clinical prognosis have been reported. Identification of the cause by genetic testing in congenital and infantile-onset FSGS is now the clinical standard, and research to discover new genes for unexplained FSGS continues. In Korea as well, multicenter studies in pediatric nephrology are under way to improve the genetic diagnostic rate of FSGS and kidney transplantation strategies.

2. Causes

The main cause of congenital nephrotic syndrome with focal segmental glomerulosclerosis is pathogenic variants in genes encoding proteins essential for maintaining podocyte structure and function. Podocytes are specialized cells that envelop the glomerular capillaries from the outside, and various molecular systems, including slit diaphragm proteins, cytoskeletal proteins, cell membrane proteins, and mitochondria-related proteins, are essential for their normal function.

The main causative genes of congenital and infantile-onset FSGS, classified as autosomal recessive and dominant, are as follows. Autosomal recessive: NPHS1(nephrin, 19q13.12), NPHS2(podocin, 1q25.2), PLCE1(phospholipase C ε1, 10q23), WT1(11p13), LAMB2(3p21), CD2AP(6p12.3), PTPRO(12p12.3), ADCK4(19q13.2), COQ6(14q24.3), etc. Autosomal dominant: ACTN4(α-actinin-4, 19q13.2), TRPC6(transient receptor potential cation channel subfamily C member 6, 11q22.1), INF2(inverted formin 2, 14q32.33), etc.

ACTN4 variants cause abnormalities of an actin filament–binding protein of the podocyte cytoskeleton, leading to reduced structural stability of podocytes and increased vulnerability to injury. The TRPC6 channel is involved in podocyte calcium signaling, and gain-of-function variants cause excessive calcium influx and podocyte injury. INF2 variants cause abnormal dynamic regulation of actin polymerization/depolymerization, impairing maintenance of podocyte morphology.

APOL1 G1 · G2 risk alleles are important genetic risk factors for adult-onset FSGS in populations of African descent, but their role in congenital onset is limited. Some mitochondrial DNA variants and variants in CoQ10 biosynthesis–related genes (ADCK4, COQ6) also cause hereditary nephrotic syndrome with FSGS histology, and they are of great diagnostic importance because they may respond to CoQ10 supplementation. In congenital FSGS, hematuria, hypertension, and early decline in renal function, in addition to proteinuria, tend to occur more often than in acquired or steroid-sensitive nephrotic syndrome.

3. Genetics

The mode of inheritance of congenital nephrotic syndrome with focal segmental glomerulosclerosis is divided into autosomal recessive (AR) and autosomal dominant (AD) depending on the causative gene. In childhood, especially with congenital and infantile onset, AR inheritance is more common, while AD inheritance is more often associated with onset in adolescence or adulthood.

AR-inherited FSGS: NPHS1 variants disrupt the core structure of the slit diaphragm, causing severe proteinuria within a few weeks to 3 months after birth. NPHS2 variants are one of the most common causes of AR hereditary SRNS; homozygous variants present in infancy to childhood, and compound heterozygous variants (especially including p.R229Q) present in adolescence to adulthood. PLCE1 variants cause infantile-onset mesangial proliferative or FSGS-type nephrotic syndrome, and have attracted attention because cases with partial response to steroid or immunosuppressive treatment have been reported in some instances.

AD-inherited FSGS: ACTN4 (19q13.2), TRPC6 (11q22.1), and INF2 (14q32.33) variants are mainly late-onset (adolescence to adulthood), but some early-onset cases have been reported. The age of onset may differ widely within a family (incomplete penetrance, variable expressivity), and AD inheritance should be suspected when FSGS appears in both children and adults within one pedigree. INF2 variants are divided into FSGS associated with Charcot-Marie-Tooth disease (INF2-CMT-FSGS) and isolated FSGS.

Genetic testing strategy: The younger the age of onset, the higher the probability of finding a gene variant. Cohort studies have found a genetic cause in about 85–90% of SRNS with onset within the first year of life. The standard test panel includes NPHS1, NPHS2, WT1, LAMB2, and PLCE1, and the extended panel adds ACTN4, TRPC6, INF2, CD2AP, ADCK4, COQ6, PTPRO, etc. Genetic diagnosis is key to deciding the indication for immunosuppressive treatment (immunosuppression is less effective when a gene variant is confirmed), assessing post-transplant recurrence risk (recurrence is rare in hereditary FSGS), and family genetic counseling.

4. General epidemiology

Focal segmental glomerulosclerosis (FSGS) is the most common histologic type of steroid-resistant nephrotic syndrome (SRNS) in both adults and children; it accounts for about 10–20% of all pediatric nephrotic syndrome, and FSGS histology is found in about 30–40% of pediatric SRNS. Congenital and infantile-onset (within the first year of life) FSGS is a minority of all FSGS, but this age group has the highest proportion of hereditary causes.

In multinational cohort studies by the International Pediatric Nephrology Association (IPNA) and the PodoNet consortium, a genetic cause was identified in about 29–66% (depending on age of onset) of children with steroid-resistant nephrotic syndrome, and the younger the age of onset, the higher the hereditary proportion. Gene variants have been reported in more than 80% of SRNS with onset before age 1 and in 30–60% with onset at 1–6 years. Regarding the distribution of causative genes by ethnicity, the NPHS2 p.R138Q variant is common in patients of European descent, and in East Asian patients such as Korean and Japanese patients, the proportion of WT1 variants, in addition to NPHS1 and NPHS2, has been reported to be relatively high.

APOL1 G1 · G2 risk alleles greatly increase the risk of FSGS in populations of West African descent, but their frequency is low in East Asian populations, so their contribution in Korean patients is negligible. Worldwide, FSGS is an important glomerular disease ranking about 2nd to 4th among causes of end-stage renal disease in adults, and in congenital and infantile-onset cases it has a major impact on healthcare resource use and quality of life because the need for renal replacement therapy (dialysis, transplantation) is brought forward into childhood. In Korea, related data are being accumulated through the pediatric chronic kidney disease database (KoreaN cohort study for Outcome in patients with Pediatric chronic kidney disease, KNOW-PedCKD) and others.

5. Pathophysiology

Focal segmental glomerulosclerosis is the final common histologic response pattern of podocyte injury. Various genetic defects impair podocyte structural maintenance, signaling, and energy metabolism, ultimately causing podocyte depletion, which leads to glomerular scarring (glomerulosclerosis).

In hereditary FSGS, the molecular mechanism of podocyte injury varies with the variant gene. NPHS1 · NPHS2 variants injure podocytes through disruption of slit diaphragm structure, ACTN4 variants through actin cytoskeletal instability, TRPC6 variants through excessive calcium influx, INF2 variants through abnormal actin dynamics, and mitochondrial/CoQ-related gene variants through abnormal energy metabolism. In common, podocyte apoptosis, detachment, and loss occur, and when the GBM is thereby exposed, sclerotic lesions form on it.

The histologic process of sclerosis formation in FSGS is as follows: ① podocyte loss (decreased podocyte/glomerular area ratio) → ② GBM exposure → ③ adhesion of mesangial cells and matrix to the GBM (synechia) → ④ nonspecific deposition (trapping) of plasma proteins (IgM, C3) in sclerotic areas → ⑤ vicious cycle of sclerotic lesion expansion and loss of resident podocytes → ⑥ sclerosis of the entire glomerulus (global sclerosis). Initially sclerosis is observed in only some glomeruli (focal, < 50% of all glomeruli), but as the disease progresses, more glomeruli and wider segments are involved (progressive FSGS).

GBM exposure and sclerosis formation are also accompanied by tubular injury, interstitial fibrosis, and tubular atrophy, leading to progressive decline in renal function. Hyperfiltration in the remaining normal glomeruli causes additional injury to the remaining podocytes, forming a vicious cycle that accelerates disease progression. The mechanism by which steroids and some immunosuppressants are effective in non-hereditary FSGS is explained by suppression of T cell–mediated circulating factors (circulating permeability factor, e.g., suPAR), but in hereditary FSGS this pathway is not involved, so there is no treatment response.

6. Symptoms

Symptoms of congenital nephrotic syndrome with focal segmental glomerulosclerosis vary depending on the underlying gene variant and the severity of histologic findings. It generally presents within the first year of life; massive proteinuria and generalized edema are the main symptoms, but hematuria, hypertension, and decreased renal function accompany it more frequently than in minimal change disease.

Proteinuria and edema: Generalized edema due to nephrotic-range proteinuria (UPCR ≥ 2.0 mg/mg) and hypoalbuminemia (< 2.5 g/dL) is the main symptom. It begins with periorbital edema and progresses to generalized edema and ascites, and dyspnea due to pleural effusion may also occur. Hyperlipidemia results from increased hepatic lipoprotein synthesis in response to hypoalbuminemia.

Hematuria: In FSGS, hematuria (microscopic hematuria) accompanies the disease more often than in minimal change disease. Gross hematuria is rare, but microscopic hematuria occurs as a result of sclerotic lesions forming in the kidney tissue.

Hypertension: Hypertension is a relatively common accompanying finding in FSGS patients, occurring due to sodium retention from declining glomerular function and activation of the renin-angiotensin-aldosterone system. In children, blood pressure at or above the 95th percentile appears, and active blood pressure control is needed to prevent cardiovascular complications.

Decline in renal function: Unlike minimal change disease, FSGS more often shows decline in renal function (elevated serum creatinine, reduced GFR) at diagnosis or during the course. As sclerosis progresses, renal function decline accelerates, and many cases progress to end-stage renal disease within childhood. Complications such as infection (sepsis, peritonitis), thrombosis (renal vein thrombosis, pulmonary embolism), malnutrition, and growth retardation occur in common with minimal change disease.

Collapsing FSGS is the most severe subtype, showing rapid decline in renal function and poor prognosis; it is rare with congenital onset but requires attention. In Denys-Drash syndrome (WT1 variants), in addition to nephrotic syndrome, male pseudohermaphroditism (abnormal genital development) and an increased risk of Wilms tumor are present. Frasier syndrome (WT1 IVS9+4C>T splicing variant) is characterized by FSGS and a disorder of sex development (XY female phenotype).

7. Signs

Physical examination findings are evaluated focusing on the degree of edema, blood pressure, growth status, and presence of associated malformations. Generalized edema (eyelids, limbs, abdomen), shifting dullness/fluid wave of ascites, and dullness to percussion from pleural effusion appear, and hypertension may be identified on blood pressure measurement.

Laboratory findings: Urinalysis may show proteinuria (4+ dipstick) and hematuria (2–3+ or microscopic RBC > 5/HPF) simultaneously. Decreased serum albumin, decreased total protein, elevated total cholesterol · LDL · TG. Elevated serum creatinine and BUN (with renal function decline). Normal serum C3 · C4 (distinguishing from infectious causes and membranoproliferative disease). Elevated blood pressure. Anemia possible on CBC. Normal complement.

Renal biopsy findings: On light microscopy, hyalinosis or sclerosis is observed in part of the glomerular tuft (segmental) in some glomeruli (focal, < 50% of glomeruli). According to the Columbia classification, it is subdivided into NOS (otherwise not specified), perihilar variant, cellular variant, tip variant, and collapsing variant. Immunofluorescence shows nonspecific trapping of IgM and C3 in sclerotic areas (mesangial or sclerotic-area deposition). Electron microscopy shows extensive effacement of podocyte foot processes, podocyte detachment and loss, and wrinkling of the GBM.

In Denys-Drash syndrome (WT1 variants), abnormal external genital development and cryptorchidism may be identified on physical examination, and early lesions of Wilms tumor (nephrogenic rests) may be seen on abdominal ultrasound. In Pierson syndrome (LAMB2 variants), microcoria is identified on slit-lamp examination. In INF2 variant–related CMT-FSGS, abnormal findings may appear on peripheral nerve conduction studies.

8. Screening

Population-wide screening of the general population is not performed. Strategies for screening and early detection of congenital FSGS nephrotic syndrome focus on high-risk groups (family history, carriers) and clinically suspected cases.

Screening within high-risk families: Neonates born into families with an affected sibling or confirmed parental carriers undergo urine protein testing (UPCR, dipstick), serum albumin, blood pressure, and serum creatinine measurement from immediately after birth. Molecular genetic analysis of the familial variant is the top priority, and affected status is confirmed early based on genetic test results. Parents who are carriers (heterozygous) of AR inheritance (NPHS1, NPHS2, etc.) are counseled that they themselves have no symptoms but transmit it to children with a 25% probability. For parents carrying AD-inherited (ACTN4, TRPC6, INF2) variants, it is explained that the same variant is transmitted to 50% of children and that the timing of onset and severity may differ even within the family.

Screening based on clinical suspicion: Nephrotic syndrome with onset within the first year of life, especially steroid-resistant nephrotic syndrome, is an indication for gene panel testing to differentiate hereditary nephrotic syndromes including hereditary FSGS. When Denys-Drash · Frasier syndrome is suspected (abnormal genital development in a male + nephrotic syndrome), WT1 gene analysis is performed first. In CoQ10 deficiency–related FSGS (ADCK4, COQ6 variants), accompanying findings such as neuromuscular symptoms, visual abnormalities, and abnormal liver enzymes provide clues.

Regular monitoring: In families carrying the NPHS2 p.R229Q variant, when compound heterozygosity of this variant with another NPHS2 variant is predicted, regular urine protein testing and blood pressure monitoring are recommended. In post-transplant patients as well, FSGS recurrence is detected early by regular monitoring of proteinuria, renal function, and blood pressure.

9. Diagnosis

Diagnosis of congenital nephrotic syndrome with focal segmental glomerulosclerosis is confirmed in three steps: meeting clinical criteria for nephrotic syndrome (massive proteinuria, hypoalbuminemia, edema), FSGS histology on renal biopsy, and genetic analysis.

Clinical criteria: Nephrotic syndrome with onset within the first year of life (within 3 months for congenital), meeting nephrotic-range proteinuria (UPCR ≥ 2.0 mg/mg or 24-hour urine protein > 40 mg/m²/hr) and hypoalbuminemia (< 2.5 g/dL). Steroid-resistant nephrotic syndrome not responding to steroid treatment (prednisolone 60 mg/m²/day for 4 weeks) is the most common clinical pattern in FSGS.

Renal biopsy: FSGS histology is confirmed by light microscopy, immunofluorescence, and electron microscopy by an experienced pediatric renal pathologist. The subtype is determined by the Columbia classification, and reduced podocyte density, degree of foot process effacement, GBM abnormalities, tubular changes, and degree of interstitial fibrosis are described quantitatively. The degree of tubulointerstitial fibrosis correlates with prognosis and is an important histologic prognostic factor.

Genetic testing: For pediatric SRNS · FSGS, the IPNA 2020 guideline recommends gene panel testing simultaneously with clinical diagnosis or in parallel with biopsy. Basic panel: NPHS1, NPHS2, WT1, LAMB2, PLCE1. Extended panel: ACTN4, TRPC6, INF2, CD2AP, ADCK4, COQ6, PTPRO, MAGI2, KIRREL, ARHGDIA, etc. If the panel is negative, diagnosis is extended with WES or WGS. Once a genetic diagnosis is confirmed, attempts at immunosuppressive treatment can be minimized and transplant preparation brought forward.

Special tests for CoQ10 deficiency–related FSGS: When ADCK4 or COQ6 variants are suspected, measurement of serum · urine CoQ10 levels and muscle biopsy (evaluation of mitochondrial function) are helpful, and because high-dose CoQ10 supplementation (600–1200 mg/day) has been reported to reduce proteinuria, a diagnostic therapeutic trial is considered.

10. Treatment

Treatment of congenital nephrotic syndrome with focal segmental glomerulosclerosis is individualized according to whether a gene variant is confirmed and the treatment response. In patients with a confirmed gene variant, immunosuppressants are ineffective in most cases, so the focus is on preserving renal function and preparing for transplantation.

Trial of steroid treatment: When no gene variant is confirmed or a VUS is found, a 4-week course of prednisolone 60 mg/m²/day (or 2 mg/kg/day) is tried. If steroid-responsive (SSNS), manage with the standard nephrotic syndrome protocol. If SRNS is confirmed, second-line immunosuppressive treatment or reconfirmation of the genetic diagnosis.

Calcineurin inhibitors (CNI): In SRNS, cyclosporine (target blood level C0 80–120 ng/mL or C2 800–1200 ng/mL) or tacrolimus (target blood level C0 4–8 ng/mL) is administered for at least 6 months. Because partial or complete remission has been reported in patients with PLCE1 variants, a CNI trial is considered in patients with this gene variant. Monitoring for long-term nephrotoxicity is essential.

Rituximab: It has been reported to reduce proteinuria in non-hereditary FSGS through a non–B cell–mediated mechanism (protective action on podocyte sphingomyelin phosphodiesterase acid-like 3b, SMPDL-3b), but its effect in hereditary FSGS is unclear. It is used as second-line treatment in steroid-dependent or frequently relapsing FSGS.

ACE inhibitors/ARBs, supportive care: In all FSGS patients, ACE inhibitors (enalapril, ramipril) or ARBs (losartan, candesartan) are given early to reduce proteinuria and preserve renal function. Edema control with intravenous albumin and diuretics, nutritional support, infection prevention (prophylactic antibiotics, vaccination), and thrombosis prevention are the core of conservative treatment.

Kidney transplantation: In hereditary FSGS, post-transplant recurrence is rare (< 10% in hereditary forms, unlike the 30–40% recurrence rate of non-hereditary FSGS), so transplant outcomes are relatively favorable. Transplantation is recommended at a body weight of 8–10 kg or more (generally 2–3 years of age). Rare cases of post-transplant recurrence have been reported with PLCE1 variants. Checking the donor kidney for NPHS2 p.R229Q/p.R229Q homozygous variants may also be included in the pre-transplant evaluation.

11. Prognosis

The prognosis of congenital nephrotic syndrome with focal segmental glomerulosclerosis varies greatly depending on the gene variant type, rate of sclerosis progression, and treatment response. Overall, many cases progress to SRNS, and most progress to end-stage renal disease within childhood, requiring renal replacement therapy.

Progression to ESRD: Patients with NPHS1 variants show the fastest progression, reaching ESRD within 2–3 years without treatment. Relatively slow progression has been reported in patients with homozygous NPHS2 variants (especially non-Finnish missense variants), and in some, renal function is maintained even beyond adolescence. In patients with PLCE1 variants with a confirmed response to CNI treatment, progression to ESRD may be delayed.

Post-transplant prognosis: In hereditary FSGS, post-transplant FSGS recurrence is markedly lower than in non-hereditary forms (< 10% vs. 30–40%). Five-year post-transplant survival is favorable, similar to general pediatric kidney transplantation. In WT1-related patients, surveillance for Wilms tumor is continuously needed even after transplantation.

Other complications: Infection, thrombosis, malnutrition, and growth retardation are important causes of mortality and morbidity before transplantation. In Denys-Drash syndrome with FSGS, Wilms tumor has been reported in up to 90%, so regular surveillance is essential. Long-term monitoring for immunosuppression-related complications after transplantation (infection, malignancy, nephrotoxicity) is important.

12. Prevention

Prevention strategies for congenital FSGS nephrotic syndrome, similar to those for minimal change disease, consist of primary prevention through genetic counseling and prenatal/preimplantation genetic testing, and secondary and tertiary prevention through early diagnosis and supportive care.

Genetic counseling and prenatal diagnosis: When the causative gene variant has been identified in parents with an affected child, prenatal genetic diagnosis or preimplantation genetic testing is offered for the next pregnancy. In families with AR-inherited FSGS (NPHS1, NPHS2, PLCE1, etc.), the 25% recurrence risk is clearly explained, and in families with AD-inherited FSGS (ACTN4, TRPC6, INF2), counseling is provided on the 50% transmission risk and incomplete penetrance.

Early diagnosis and preservation of renal function: In neonates from high-risk families, early genetic diagnosis and urine protein monitoring allow treatment to start immediately upon symptom onset. ACE inhibitors/ARBs are given early to minimize proteinuria and suppress glomerular hyperfiltration. Blood pressure is maintained at the target level (< 50th percentile). Prevention of infection · thrombosis prevents deterioration of renal function due to complications.

Wilms tumor surveillance (WT1-related): In patients with Denys-Drash or Frasier syndrome, Wilms tumor is monitored by abdominal ultrasound every 3–6 months. Prophylactic nephrectomy is considered when diffuse mesangial sclerosis is confirmed histologically. Collaboration with an endocrinology · urology specialist team for disorders of sex development is needed.


13. References

  1. D'Agati VD, Kaskel FJ, Falk RJ. Focal segmental glomerulosclerosis. N Engl J Med. 2011;365(25):2398-2411. DOI: 10.1056/NEJMra1106556. PMID: 22187987.
  2. Kaplan JM, Kim SH, North KN, et al. Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis. Nat Genet. 2000;24(3):251-256. DOI: 10.1038/73456. PMID: 10700177.
  3. Hinkes BG, Mucha B, Vlangos CN, et al. Nephrotic syndrome in the first year of life: two thirds of cases are caused by mutations in 4 genes (NPHS1, NPHS2, WT1, and LAMB2). Pediatrics. 2007;119(4):e907-e919. DOI: 10.1542/peds.2006-2164. PMID: 17371942.
  4. Brown EJ, Schlöndorff JS, Becker DJ, et al. Mutations in the formin gene INF2 cause focal segmental glomerulosclerosis. Nat Genet. 2010;42(1):72-76. DOI: 10.1038/ng.505. PMID: 19966804.
  5. Trautmann A, Vivarelli M, Samuel S, et al. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2020;35(8):1529-1561. DOI: 10.1007/s00467-020-04519-1. PMID: 32382828.
  6. Sadowski CE, Lovric S, Ashraf S, et al. A single-gene cause in 29.5% of cases of steroid-resistant nephrotic syndrome. J Am Soc Nephrol. 2015;26(6):1279-1289. DOI: 10.1681/ASN.2014050489. PMID: 25349199.
  7. Zenker M, Aigner T, Wendler O, et al. Human laminin beta2 deficiency causes congenital nephrosis with mesangial sclerosis and distinct eye abnormalities. Hum Mol Genet. 2004;13(21):2625-2632. DOI: 10.1093/hmg/ddh284. PMID: 15367484.
  8. Gbadegesin RA, Winn MP, Smoyer WE. Genetic testing in nephrotic syndrome — challenges and opportunities. Nat Rev Nephrol. 2013;9(10):582-596. DOI: 10.1038/nrneph.2013.178. PMID: 23999399.
  9. Saleem MA. New developments in steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2013;28(5):699-709. DOI: 10.1007/s00467-012-2239-x. PMID: 22729532.
  10. Kim JH, Han KH, Lee JM, et al. Genetic and clinical characteristics of childhood-onset nephrotic syndrome in Korea. J Korean Med Sci. 2019;34(6):e55. DOI: 10.3346/jkms.2019.34.e55. PMID: 30799572.